Ixazomib: a novel drug for multiple myeloma

Saurabh Zanwar, Jithma Prasad Abeykoon, Prashant Kapoor

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.

Original languageEnglish (US)
Pages (from-to)761-771
Number of pages11
JournalExpert Review of Hematology
Volume11
Issue number10
DOIs
StatePublished - Oct 3 2018

Fingerprint

Multiple Myeloma
Proteasome Inhibitors
Pharmaceutical Preparations
Safety
ixazomib
Pharmacology
Therapeutics

Keywords

  • maintenance therapy
  • novel agent
  • Oral anti-myeloma therapy
  • quality of life
  • small molecule proteasome inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Ixazomib : a novel drug for multiple myeloma. / Zanwar, Saurabh; Abeykoon, Jithma Prasad; Kapoor, Prashant.

In: Expert Review of Hematology, Vol. 11, No. 10, 03.10.2018, p. 761-771.

Research output: Contribution to journalArticle

Zanwar, Saurabh ; Abeykoon, Jithma Prasad ; Kapoor, Prashant. / Ixazomib : a novel drug for multiple myeloma. In: Expert Review of Hematology. 2018 ; Vol. 11, No. 10. pp. 761-771.
@article{1648204f9c514e45b9a136ef8f7c54de,
title = "Ixazomib: a novel drug for multiple myeloma",
abstract = "Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.",
keywords = "maintenance therapy, novel agent, Oral anti-myeloma therapy, quality of life, small molecule proteasome inhibitor",
author = "Saurabh Zanwar and Abeykoon, {Jithma Prasad} and Prashant Kapoor",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/17474086.2018.1518129",
language = "English (US)",
volume = "11",
pages = "761--771",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Ixazomib

T2 - a novel drug for multiple myeloma

AU - Zanwar, Saurabh

AU - Abeykoon, Jithma Prasad

AU - Kapoor, Prashant

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.

AB - Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.

KW - maintenance therapy

KW - novel agent

KW - Oral anti-myeloma therapy

KW - quality of life

KW - small molecule proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85054056290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054056290&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1518129

DO - 10.1080/17474086.2018.1518129

M3 - Article

C2 - 30173621

AN - SCOPUS:85054056290

VL - 11

SP - 761

EP - 771

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 10

ER -